AUD 0.04
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2024 | 12.5 Thousand AUD | -96.97% |
2023 | 412.16 Thousand AUD | -83.04% |
2022 | 224.61 Thousand AUD | -30.43% |
2021 | 322.85 Thousand AUD | -30.09% |
2020 | 461.84 Thousand AUD | 95.83% |
2019 | 235.84 Thousand AUD | 101.29% |
2018 | 117.16 Thousand AUD | 0.0% |
2017 | - AUD | -100.0% |
2016 | 11.63 Thousand AUD | 0.0% |
2015 | - AUD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 FY | 12.5 Thousand AUD | -67.19% |
2024 Q2 | 875.00 AUD | -29.05% |
2024 Q4 | 11.62 Thousand AUD | -96.02% |
2023 Q2 | - AUD | 0.0% |
2023 Q4 | 38.1 Thousand AUD | 0.0% |
2023 FY | 38.1 Thousand AUD | -83.04% |
2022 Q2 | - AUD | 0.0% |
2022 FY | 224.61 Thousand AUD | -30.43% |
2022 Q4 | 224.61 Thousand AUD | 0.0% |
2021 Q4 | 322.85 Thousand AUD | 0.0% |
2021 Q2 | - AUD | 0.0% |
2021 FY | 322.85 Thousand AUD | -30.09% |
2020 Q2 | 461.84 Thousand AUD | 0.0% |
2020 FY | 461.84 Thousand AUD | 95.83% |
2020 Q4 | - AUD | 0.0% |
2019 FY | 235.84 Thousand AUD | 101.29% |
2019 Q4 | 235.84 Thousand AUD | 0.0% |
2019 Q2 | - AUD | 0.0% |
2018 FY | 117.16 Thousand AUD | 0.0% |
2018 Q4 | 117.16 Thousand AUD | 0.0% |
2018 Q2 | - AUD | 0.0% |
2017 Q4 | - AUD | 0.0% |
2017 Q1 | - AUD | 0.0% |
2017 FY | - AUD | -100.0% |
2017 Q3 | - AUD | 0.0% |
2017 Q2 | - AUD | 0.0% |
2016 FY | 11.63 Thousand AUD | 0.0% |
2015 FY | - AUD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AdAlta Limited | 1.73 Million AUD | 99.281% |
Acrux Limited | 5.09 Million AUD | 99.754% |
Actinogen Medical Limited | 9.93 Million AUD | 99.874% |
AnteoTech Limited | 460.39 Thousand AUD | 97.285% |
Argenica Therapeutics Limited | 2.59 Million AUD | 99.519% |
Arovella Therapeutics Limited | 17 Thousand AUD | 26.465% |
Anatara Lifesciences Ltd | - AUD | -Infinity% |
Alterity Therapeutics Limited | 4.01 Million AUD | 99.689% |
Amplia Therapeutics Limited | 4.45 Million AUD | 99.719% |
Avecho Biotechnology Limited | 473.55 Thousand AUD | 97.36% |
Bio-Gene Technology Limited | 18.32 Thousand AUD | 31.763% |
Biome Australia Limited | 13 Million AUD | 99.904% |
Biotron Limited | - AUD | -Infinity% |
Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | 97.923% |
BTC Health Limited | 16.36 Thousand AUD | 23.588% |
Chimeric Therapeutics Limited | 7.45 Million AUD | 99.832% |
CSL Limited | 22.41 Billion AUD | 100.0% |
Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 99.891% |
Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 99.986% |
Cynata Therapeutics Limited | 2.31 Million AUD | 99.46% |
Dimerix Limited | 583.47 Thousand AUD | 97.858% |
EZZ Life Science Holdings Limited | 66.44 Million AUD | 99.981% |
Hexima Limited | - AUD | -Infinity% |
Island Pharmaceuticals Limited | 1.25 Million AUD | 99.001% |
Immuron Limited | 4.9 Million AUD | 99.745% |
Immutep Limited | 3.5 Million AUD | 99.643% |
Imugene Limited | - AUD | -Infinity% |
Invex Therapeutics Ltd | 1.21 Million AUD | 98.969% |
Memphasys Limited | 60 Thousand AUD | 79.165% |
Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.995% |
Noxopharm Limited | 2.4 Million AUD | 99.479% |
NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
Nyrada Inc. | - AUD | -Infinity% |
Orthocell Limited | 5.31 Million AUD | 99.765% |
PharmAust Limited | - AUD | -Infinity% |
Patrys Limited | 1.39 Million AUD | 99.103% |
Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | 81.002% |
Proteomics International Laboratories Limited | 892.14 Thousand AUD | 98.599% |
Prescient Therapeutics Limited | 3.71 Million AUD | 99.663% |
PYC Therapeutics Limited | 22.05 Million AUD | 99.943% |
Race Oncology Limited | 4 Million AUD | 99.688% |
Radiopharm Theranostics Limited | 299.22 Thousand AUD | 95.822% |
Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
Starpharma Holdings Limited | 8.28 Million AUD | 99.849% |
Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.997% |
Tissue Repair Ltd | 152.24 Thousand AUD | 91.789% |
Zelira Therapeutics Limited | 94.95 Thousand AUD | 86.834% |